Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant
Fulvestrant degrades the oestrogen receptor. Here, the authors report on a clinical trial using fulvestrant and show that mutations in the oestrogen receptor alpha gene are prevalent in circulating tumour DNA and do not influence the clinical outcome of patients to fulvestrant.
Guardado en:
Autores principales: | Jill M. Spoerke, Steven Gendreau, Kimberly Walter, Jiaheng Qiu, Timothy R. Wilson, Heidi Savage, Junko Aimi, Mika K. Derynck, Meng Chen, Iris T. Chan, Lukas C. Amler, Garret M. Hampton, Stephen Johnston, Ian Krop, Peter Schmid, Mark R. Lackner |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2016
|
Materias: | |
Acceso en línea: | https://doaj.org/article/3ed6583a52b645a290a897ba20ac7a5f |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer
por: Lillian M. Smyth, et al.
Publicado: (2021) -
A preliminary study of 18F-FES PET/CT in predicting metastatic breast cancer in patients receiving docetaxel or fulvestrant with docetaxel
por: Chengcheng Gong, et al.
Publicado: (2017) -
Prognostic Value of Tumor Heterogeneity on 18F-FDG PET/CT in HR+HER2− Metastatic Breast Cancer Patients receiving 500 mg Fulvestrant: a retrospective study
por: Yannan Zhao, et al.
Publicado: (2018) -
Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer
por: Ben O’Leary, et al.
Publicado: (2018) -
Preliminary results of using ESR to examine biofilms
por: Whitehead,Neil Evan, et al.
Publicado: (2004)